Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
PLoS One. 2010 Oct 28;5(10):e13711. doi: 10.1371/journal.pone.0013711.
While many studies have compared the efficacy of Pap cytology, visual inspection with acetic acid (VIA) and human papillomavirus (HPV) DNA assays for the detection cervical intraepithelial neoplasia and cancer, few have evaluated the program effectiveness.
A population-based sample of 5603 women from Medchal Mandal in Andhra Pradesh, India were invited to participate in a study comparing Pap cytology, VIA, and HPV DNA screening for the detection of CIN3+. Participation in primary screening and all subsequent follow-up visits was rigorously tracked. A 20% random sample of all women screened, in addition to all women with a positive screening test result underwent colposcopy with directed biopsy for final diagnosis. Sensitivity, specificity, positive and negative predictive values were adjusted for verification bias. HPV testing had a higher sensitivity (100%) and specificity (90.6%) compared to Pap cytology (sensitivity = 78.2%; specificity = 86.0%) and VIA (sensitivity = 31.6%; specificity = 87.5%). Since 58% of the sample refused involvement and another 28% refused colposcopy or biopsy, we estimated that potentially 87.6% of the total underlying cases of CIN3 and cancer may have been missed due to program failures.
We conclude that despite our use of available resources, infrastructure, and guidelines for cervical cancer screening implementation in resource limited areas, community participation and non-compliance remain the major obstacles to successful reduction in cervical cancer mortality in this Indian population. HPV DNA testing was both more sensitive and specific than Pap cytology and VIA. The use of a less invasive and more user-friendly primary screening strategy (such as self-collected swabs for HPV DNA testing) may be required to achieve the coverage necessary for effective reduction in cervical cancer mortality.
许多研究比较了巴氏细胞学、醋酸视觉检查(VIA)和人乳头瘤病毒(HPV)DNA 检测在宫颈癌前病变和癌症检测中的效果,但很少有研究评估这些检测方法的实际效果。
印度安得拉邦 Medchal Mandal 地区的一个基于人群的 5603 名女性样本被邀请参加一项研究,比较巴氏细胞学、VIA 和 HPV DNA 筛查对 CIN3+的检测效果。严格跟踪所有女性参与初级筛查以及所有后续随访的情况。对所有接受筛查的女性进行了 20%的随机抽样,以及所有筛查阳性的女性都进行阴道镜检查和定向活检,以确定最终诊断。调整了验证偏差的灵敏度、特异性、阳性和阴性预测值。HPV 检测的敏感性(100%)和特异性(90.6%)均高于巴氏细胞学(敏感性为 78.2%,特异性为 86.0%)和 VIA(敏感性为 31.6%,特异性为 87.5%)。由于 58%的样本拒绝参与,另有 28%的样本拒绝阴道镜检查或活检,我们估计,由于项目失败,可能有 87.6%的 CIN3 和癌症总潜在病例被遗漏。
我们的结论是,尽管我们利用了资源、基础设施和指南来实施资源有限地区的宫颈癌筛查,但社区参与度低和不遵守规定仍然是成功降低印度人口宫颈癌死亡率的主要障碍。HPV DNA 检测的敏感性和特异性均高于巴氏细胞学和 VIA。为了实现有效降低宫颈癌死亡率所需的覆盖率,可能需要使用更具侵入性和更易用的初级筛查策略(如 HPV DNA 检测的自我采集拭子)。